Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer

Cancer Biology and Therapy

Volumn 12, Issue 5, 2011, Pages 407-420

  Aljuffali, Ibrahim A ^a,c   Mock, Jason N ^a   Costyn, Leah J ^a   Nguyen, Ha ^a   Nagy, Tamas ^b   Cummings, Brian S ^a   Arnold, Robert D ^a  

^a Department of Pharmacy and Toxicology   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Cancer; Dosing schedules; Metronomic; p21 and cell cycle; Prostate; Topotecan

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CELL PROTEIN; LIPOCORTIN 5; PROPIDIUM IODIDE; TOPOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SIZE; CELL COUNT; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRUCTURE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN GEL BLOT ANALYSIS; STAINING;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; MALE; MICE; MICE, NUDE; MITOCHONDRIA; PROSTATIC NEOPLASMS; TOPOTECAN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80052356005     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.5.15950     Document Type: Article

References (51)

1. Gulley J., Dahut W. Novel clinical trials in androgenindependent prostate cancer. Clin Prostate Cancer 2002; 1:51-57; PMID: 15046713.
2. Thompson I., Thrasher J.B., Aus G., Burnett AL, Canby- Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177:2106-31; PMID: 17509297; DOI: 10.1016/j.juro.2007.03.003.
3. Jani AB. Management strategies for locally advanced prostate cancer. Drugs Aging 2006; 23:119-29; PMID: 16536635; DOI: 10.2165/00002512-200623020- 00003.
4. Rumohr J.A., Chang S.S. Current chemotherapeutic approaches for androgen-independent prostate cancer. Curr Opin Investig Drugs 2006; 7:529-533; PMID: 16784023.
5. Feldman B.J., Feldman D. The development of androgen- independent prostate cancer. Nat Rev Cancer 2001; 1:34-45; PMID: 11900250; DOI: 10.1038/35094009.
6. Seruga B., Ocana A., Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8:12-23 PMID:20859283; DOI: 10.1038/ nrclinonc.2010.136.
7. Kerbel R.S., Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4:423-36; PMID: 15170445; DOI: 10.1038/nrc1369.
8. Kerbel R.S., Klement G., Pritchard K.I., Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 13:12-5; PMID: 11863092; DOI: 10.1093/annonc/mdf093.
9. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271:58-65; PMID: 8066425; DOI: 10.1038/scientificamerican0794-58.
10. Berry W., Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005; 10:30-9; PMID: 16368869; DOI: 10.1634/theoncologist.10-90003-30.
11. Lennernäs B., Albertsson P., Damber J.E., Norrby K. Albertsson P, Damber J, Norrby K. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. APMIS 2004; 112:201-9; PMID: 15153162; DOI: 10.1111/j.1600-0463.2004. apm1120306.x.
12. Vogt T., Hafner C., Bross K., Bataille F., Jauch K., Berand A., et al. Antiangiogenetic therapy with pioglitazone, rofecoxib and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 2003; 98:2251-6; PMID: 14601096; DOI: 10.1002/ cncr.11775.
13. Colleoni M., Orlando L., Sanna G., Rocca A., Maisonneuve P., Peruzzotti G., et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006; 17:232-8; PMID: 16322118; DOI: 10.1093/annonc/mdj066.
14. Kamat A.A., Kim T., Landen C. Jr, Lu C., Han L., Lin Y., et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007; 67:281-8; PMID: 17210709; DOI: 10.1158/0008-5472.CAN- 06-3282.
15. Bocci G., Falcone A., Fioravanti A., Orlandi P., Di Paolo A., Fanelli G., et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 2008; 98:1619-29; PMID: 18443598; DOI: 10.1038/ sj.bjc.6604352.
16. Wang J., Lou P., Lesniewski R., Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003; 14:13-9; PMID: 12544254; DOI: 10.1097/00001813-200301000-00003.
17. Fontana A., Galli L., Fioravanti A., Orlandi P., Galli C., Landi L., et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009; 15:4954-62; PMID: 19622584; DOI: 10.1158/1078-0432.CCR-08- 3317.
18. Bocci G., Nicolaou K., Kerbel R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62:6938-6943; PMID: 12460910.
19. Miller K.D., Sweeney C., Sledge G. Jr. Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19:1195-1206; PMID: 11181686.
20. Doloff J.C., Khan N., Ma J., Demidenko E., Swartz H., Jounaidi Y. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine (Sup. Material). Curr Cancer Drug Targets 2009; 9:777-88; PMID: 19754361; DOI: 10.2174/156800909789271503.
21. O'Leary J.J., Shapiro R.L., Ren C.J., Chuang N., Cohen H.W., Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan and CPT-11 studied in the mouse cornea model. Clin Cancer Res 1999; 5:181-187; PMID: 9918217.
22. Clements M.K., Jones C.B., Cumming M., Daoud SS. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol 1999; 44:411-6; PMID: 10501915; DOI: 10.1007/s002800050997.
23. Petrangolini G., Pratesi G., De Cesare M., Supino R., Pisano C., Marcellini M., et al. Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol Cancer Res 2003; 1:863-870; PMID: 14573787.
24. Hsiang Y.H., Liu L. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48:1722-1726; PMID: 2832051.
25. Hudes G.R., Kosierowski R., Greenberg R., Ramsey H., Fox S., Ozols R., et al. Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest New Drugs 1995; 13:235-40; PMID: 8729952; DOI: 10.1007/BF00873806.
26. Klein C.E., Tangen C.M., Braun T.J., Hussain M.H., Peereboom D.M., Nichols C.R., et al. SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study. Prostate 2002; 52:264-8; PMID: 12210486; DOI: 10.1002/ pros.10118.
27. Tolis C., Peters G.J., Ferreira C.G., Pinedo H.M., Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 1999; 35:796-807; PMID: 10505042; DOI: 10.1016/S0959-8049(98)00425-0.
28. 2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms. J Pharmacol Exp Ther 2008; 326:59-68; PMID: 18441250; DOI: 10.1124/jpet.108.138958.
29. Sun B., Zhang X., Yonz C., Cummings BS. Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells. Biochem Pharmacol 2010; 79:1727-35; PMID: 20171194; DOI: 10.1016/j.bcp.2010.02.005.
30. Kaiser M.G., Parsa A., Fine R., Hall J., Chakrabarti I., Bruce J. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000; 47:1391-8; PMID: 11126910; DOI: 10.1097/00006123-200012000-00026.
31. Soffer S.Z., Kim E., Moore J., Huang J., Yokoi A., Manley C., et al. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor* 1. J Pediatr Surg 2001; 36:1781-4; PMID: 11733906; DOI: 10.1053/jpsu.2001.28823.
32. Horoszewicz J.S., Leong S., Kawinski E., Karr J., Rosenthal H., Chu T., et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43:1809-1818; PMID: 6831420.
33. Kaighn M.E., Narayan K., Ohnuki Y., Lechner J., Jones L. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17:16-23; PMID: 447482.
34. Price P.M., Safirstein R.L., Megyesi J. The cell cycle and acute kidney injury. Kidney Int 2009; 76:604-13; PMID: 19536080; DOI: 10.1038/ki.2009.224.
35. Jiang M., Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther 2008; 327:300-7; PMID: 18682572; DOI: 10.1124/ jpet.108.139162.
36. Cummings B.S., Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 2002; 302:8-17; PMID: 12065694; DOI: 10.1124/jpet.302.1.8.
37. Megyesi J., Udvarhelyi N., Safirstein R.L., Price P.M. The p53-independent activation of transcription of p21WAF1/ CIP1/SDI1 after acute renal failure. Am J Physiol 1996; 271:1211-1216; PMID: 8997395.
38. Niculescu A.B., III, Chen X., Smeets M., Hengst L., Prives C., Reed S. Effects of p21Cip1/Waf1 at both the G1/S and the G2/M cell cycle transitions: PRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998; 18:629-643; PMID: 9418909.
39. Dergham S., Dugan M., Joshi U., Chen Y., Du W., Smith D., et al. The clinical significance of p21WAF1/ CIP-1 and p53 expression in pancreatic adenocarcinoma. Cancer 1997; 80:372-81; DOI: 10.1002/ (SICI)1097-0142(19970801) 80:3⟨372::AIDCNCR4⟩3.0.CO;2-U.
40. Aaltomaa S., Lipponen P., Eskelinen M., Ala-Opas M., Kosma V. Prognostic value and expression of p21(waf1/ cip1) protein in prostate cancer. Prostate 1999; 39:8- 15; PMID: 10221260; DOI: 10.1002/(SICI)1097- 0045(19990401)39: 1⟨8::AID-PROS2⟩3.0.CO;2-N.
41. Gomyo Y., Ikeda M., Osaki M., Tatebe S., Tsujitani S., Ikeguchi M., et al. Expression of p21(waf1/cip1/ sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997; 79:2067-72; PMID: 9179052; DOI: 10.1002/ (SICI)1097-0142(19970601)79:11⟨2067:: AIDCNCR3⟩ 3.0.CO;2-M.
42. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004; 17:292-306; PMID: 14976540; DOI: 10.1038/modpathol. 3800054.
43. Tillmanns T., Buller R., Stewart C., Mac Eachern J., Schaiquevich P., Walker M., et al. Daily oral topotecan: Utilization of a metronomic dosing schedule to treat recurrent or persistent solid tumors. [Presented at American Society of Clinical Oncology Annual Meeting]. Chemotherapy 2008; 3:19.
44. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63; PMID: 6606682; DOI: 10.1016/0022- 1759(83)90303-4.
45. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-12; PMID: 2359136; DOI: 10.1093/ jnci/82.13.1107.
46. Davol P.A., Frackelton A.R. Jr. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: characterizing and circumventing mechanisms of tumor resistance. Prostate 1999; 40:178-91; PMID: 10398280; DOI: 10.1002/ (SICI)1097-0045(19990801)40: 3⟨178::AIDPROS6⟩ 3.0.CO;2-I.
47. Geran R., Greenberg N., MacDonald M., Schumacher A., Abbott B. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 1972; 3:1-103.
48. Tardi P., Choice E., Masin D., Redelmeier T., Bally M., Madden T.D. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 2000; 60:3389-3393; PMID: 10910044.
49. Venditto V.J., Simanek EE. Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm 2010; 7:307-49; PMID: 20108971; DOI: 10.1021/mp900243b.
50. Shah D.K., Shin B.S., Veith J., Toth K., Bernacki R.J., Balthasar JP. Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther 2009; 329:580-91; PMID: 19233938; DOI: 10.1124/jpet.108.149443.
51. Zastre J., Anantha M., Ramsay E., Bally M. Irinotecancisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother Pharmacol 2007; 60:91-102; PMID: 17009029; DOI: 10.1007/s00280-006-0353-z.